160 related articles for article (PubMed ID: 7576963)
1. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma.
Christiansen H; Sahin K; Berthold F; Hero B; Terpe HJ; Lampert F
Eur J Cancer; 1995; 31A(4):541-4. PubMed ID: 7576963
[TBL] [Abstract][Full Text] [Related]
2. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D
Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824
[TBL] [Abstract][Full Text] [Related]
3. MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A
Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors.
Combaret V; Lasset C; Frappaz D; Bouvier R; Thiesse P; Rebillard AC; Philip T; Favrot MC
Eur J Cancer; 1995; 31A(4):545-9. PubMed ID: 7576964
[TBL] [Abstract][Full Text] [Related]
5. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
[TBL] [Abstract][Full Text] [Related]
6. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma.
Combaret V; Gross N; Lasset C; Frappaz D; Beretta-Brognara C; Philip T; Beck D; Favrot MC
Eur J Cancer; 1997 Oct; 33(12):2101-5. PubMed ID: 9516862
[TBL] [Abstract][Full Text] [Related]
8. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity for chromosome 1p in familial neuroblastoma.
Tonini GP; Lo Cunsolo C; Cusano R; Iolascon A; Dagnino M; Conte M; Milanaccio C; De Bernardi B; Mazzocco K; Scaruffi P
Eur J Cancer; 1997 Oct; 33(12):1953-6. PubMed ID: 9516831
[TBL] [Abstract][Full Text] [Related]
10. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
[TBL] [Abstract][Full Text] [Related]
11. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis.
Wang H; Wang X; Xu L
Ital J Pediatr; 2023 Oct; 49(1):145. PubMed ID: 37904225
[TBL] [Abstract][Full Text] [Related]
13. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
[TBL] [Abstract][Full Text] [Related]
14. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
Bown N; Cotterill S; Lastowska M; O'Neill S; Pearson AD; Plantaz D; Meddeb M; Danglot G; Brinkschmidt C; Christiansen H; Laureys G; Speleman F; Nicholson J; Bernheim A; Betts DR; Vandesompele J; Van Roy N
N Engl J Med; 1999 Jun; 340(25):1954-61. PubMed ID: 10379019
[TBL] [Abstract][Full Text] [Related]
15. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
Martinsson T; Sjöberg RM; Hedborg F; Kogner P
Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
[TBL] [Abstract][Full Text] [Related]
16. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1.
Ohtsu K; Hiyama E; Ichikawa T; Matsuura Y; Yokoyama T
Clin Cancer Res; 1997 Jul; 3(7):1221-8. PubMed ID: 9815803
[TBL] [Abstract][Full Text] [Related]
17. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
[TBL] [Abstract][Full Text] [Related]
18. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
Simon T; Spitz R; Faldum A; Hero B; Berthold F
J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
[TBL] [Abstract][Full Text] [Related]
19. Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome.
Iolascon A; Lo Cunsolo C; Giordani L; Cusano R; Mazzocco K; Boumgartner M; Ghisellini P; Faienza MF; Boni L; De Bernardi B; Conte M; Romeo G; Tonini GP
Cancer Lett; 1998 Aug; 130(1-2):83-92. PubMed ID: 9751260
[TBL] [Abstract][Full Text] [Related]
20. The current contribution of molecular factors to risk estimation in neuroblastoma patients.
Berthold F; Sahin K; Hero B; Christiansen H; Gehring M; Harms D; Horz S; Lampert F; Schwab M; Terpe J
Eur J Cancer; 1997 Oct; 33(12):2092-7. PubMed ID: 9516860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]